Corporate ProfileWe are a clinical stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation.
Data provided by Nasdaq. Minimum 15 minutes delayed.
Jan 31, 2017AnaptysBio Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
There are currently no events scheduled.